Article
Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.
Cell death & disease - 6 Dec 2023
Vogt Melina, Dienstbier Niklas, Schliehe-Diecks Julian, Scharov Katerina, Tu Jia-Wey, Gebing Philip, Hogenkamp Julian, Bilen Berna-Selin, Furlan Silke, Picard Daniel, Remke Marc, Yasin Layal, Bickel David, Kalia Munishikha, Iacoangeli Alfredo, Lenz Thomas, Stühler Kai, Pandyra Aleksandra A, Hauer Julia, Fischer Ute, Wagener Rabea, Borkhardt Arndt, Bhatia Sanil
Abstract excerpt
HSP90 has emerged as an appealing anti-cancer target. However, HSP90 inhibitors (HSP90i) are characterized by limited clinical utility, primarily due to the resistance acquisition via heat shock response (HSR) induction. Understanding the roles of abundantly expressed cytosolic HSP90 isoforms (α and β) in sustaining malignant cells' growth and the mechanisms of resistance to HSP90i is crucial for exploiting their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.